AGIOAgios Pharmaceuticals, Inc.

33.09USD-5.78%Mkt Cap: 1.98B $P/E:

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-ty…

Key Statistics

Company
Market Cap1.98B $
Enterprise Value1.42B $
Revenue (TTM)98.34M $
Gross Profit47.68M $
Net Income (TTM)-412.78M $
Revenue/Share1.675 USD
Last Price33.09 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees539
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS00847X1046
Valuation
P/E (Trailing)
P/E (Forward)-8.52
PEG
EV/EBITDA-3.13
EV/Revenue14.45
P/S20.42
P/B1.95
EPS (TTM)-6.71
EPS (Forward)-3.95
52W Range
22.2446% of range46.00
52W High46.00 USD
52W Low22.24 USD
Profitability
Gross Margin88.26%
Oper. Margin-247.07%
EBITDA Margin0.00%
Profit Margin-764.01%
ROE-34.60%
ROA-31.82%
Growth
Revenue Growth259.30%
Earnings Growth
Cash Flow & Leverage
Operating CF-372.98M $
CapEx (TTM)14.32M $
FCF Margin-279.25%
FCF Yield-13.90%
Net Debt-586.40M $
Net Debt/EBITDA1.29
Balance Sheet
Debt/Equity0.03
Current Ratio10.22
Quick Ratio9.14
Book Value/Sh17.21 USD
Cash/Share10.34 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)45.75 USD
Upside (mean)+38.3%
Target Range32.00 USD73.00 USD
$32.00+38.3% to mean$73.00
# Analysts8
Ownership
Shares Out.59.70M
Float50.02M
Insiders1.07%
Institutions112.34%
Short Interest
Short Ratio5.7d
Short % Float11.58%
Short % Out.11.46%
Shares Short6.84M
Short (prev mo.)6.76M
Technical
SMA 5035.48 (-6.7%)
SMA 20030.96 (+6.9%)
Beta0.59
S&P 52W Chg18.16%
Avg Vol (30d)1.07M
Avg Vol (10d)1.12M
Technical Indicators
RSI (14)45.8
MACD-0.4944
MACD Signal-0.6386
MACD Hist.+0.1442
BB Upper37.42 USD
BB Middle33.49 USD
BB Lower29.56 USD
BB Width23.47%
ATR (14)1.767 USD
Vol Ratio (20d)0.50x